S&P 500   3,093.57 (-0.02%)
DOW   27,750.97 (-0.12%)
QQQ   201.20 (-0.19%)
CGC   15.91 (-14.00%)
BABA   181.75 (-0.40%)
GE   11.27 (-0.18%)
T   38.80 (-0.92%)
F   8.79 (-0.23%)
ACB   3.25 (-8.45%)
BAC   32.60 (-0.58%)
DIS   147.89 (-0.56%)
S&P 500   3,093.57 (-0.02%)
DOW   27,750.97 (-0.12%)
QQQ   201.20 (-0.19%)
CGC   15.91 (-14.00%)
BABA   181.75 (-0.40%)
GE   11.27 (-0.18%)
T   38.80 (-0.92%)
F   8.79 (-0.23%)
ACB   3.25 (-8.45%)
BAC   32.60 (-0.58%)
DIS   147.89 (-0.56%)
S&P 500   3,093.57 (-0.02%)
DOW   27,750.97 (-0.12%)
QQQ   201.20 (-0.19%)
CGC   15.91 (-14.00%)
BABA   181.75 (-0.40%)
GE   11.27 (-0.18%)
T   38.80 (-0.92%)
F   8.79 (-0.23%)
ACB   3.25 (-8.45%)
BAC   32.60 (-0.58%)
DIS   147.89 (-0.56%)
S&P 500   3,093.57 (-0.02%)
DOW   27,750.97 (-0.12%)
QQQ   201.20 (-0.19%)
CGC   15.91 (-14.00%)
BABA   181.75 (-0.40%)
GE   11.27 (-0.18%)
T   38.80 (-0.92%)
F   8.79 (-0.23%)
ACB   3.25 (-8.45%)
BAC   32.60 (-0.58%)
DIS   147.89 (-0.56%)
Log in

Aileron Therapeutics Stock Price, Forecast & Analysis (NASDAQ:ALRN)

$0.52
+0.02 (+4.00 %)
(As of 11/14/2019 02:33 PM ET)
Today's Range
$0.51
Now: $0.52
$0.52
50-Day Range
$0.41
MA: $0.52
$0.86
52-Week Range
$0.40
Now: $0.52
$2.60
Volume113 shs
Average Volume809,706 shs
Market Capitalization$14.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share

Profitability

Net Income$-31,550,000.00

Miscellaneous

Employees23
Market Cap$14.46 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.


Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. View Aileron Therapeutics' Earnings History.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aileron Therapeutics.

What price target have analysts set for ALRN?

3 Wall Street analysts have issued 12-month target prices for Aileron Therapeutics' stock. Their forecasts range from $5.00 to $6.00. On average, they expect Aileron Therapeutics' stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 957.7% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

What is the consensus analysts' recommendation for Aileron Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

What are Wall Street analysts saying about Aileron Therapeutics stock?

Here are some recent quotes from research analysts about Aileron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. " (11/12/2019)
  • 2. HC Wainwright analysts commented, "Our $6 price target is based on probability-adjusted forecasts for ALRN-6924 for myelopreservation, and ALRN-6924 in combination with Ibrance in MDM2-amplified solid tumor patients." (9/11/2019)

Has Aileron Therapeutics been receiving favorable news coverage?

News coverage about ALRN stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aileron Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Aileron Therapeutics.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 725,100 shares, an increase of 424.7% from the September 30th total of 138,200 shares. Based on an average daily trading volume, of 517,100 shares, the short-interest ratio is currently 1.4 days. Approximately 4.3% of the shares of the company are sold short. View Aileron Therapeutics' Current Options Chain.

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
  • Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)
  • Mr. Richard J. Wanstall, VP of Fin. & Operations
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.52.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $14.46 million. The company earns $-31,550,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is http://www.aileronrx.com/.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]


MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel